An international expert panel published updated 2026 consensus recommendations on the safe use of CAR T-cell therapy for severe, treatment-refractory autoimmune disease in The Lancet Rheumatology. The guidance aims to standardize risk mitigation as autoimmune indications expand, where dosing, monitoring, and patient selection can differ from oncology settings.